← FDA DRUG APPROVALS

FDA NDA · NDA213218

SOAANZ

torsemide

Sponsor: SARFE PHARMS

APPLICATION
NDA213218
TYPE
NDA
ORIGINAL APPROVAL
2021-06-14
LATEST ACTION
2021-11-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued, Prescription

Products

SOAANZ · ReferenceDiscontinued
TORSEMIDE 60MG · TABLET · ORAL
SOAANZ · ReferencePrescription
TORSEMIDE 40MG · TABLET · ORAL
SOAANZ · ReferenceDiscontinued
TORSEMIDE 20MG · TABLET · ORAL

Approval history

2021-11-17Manufacturing (CMC) · Supplement 1 — Label ↗AP
2021-06-14Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →